Search
Cytokinetics Inc
CYTKAdd to Watchlist
78.780USD
+0.670+0.86%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
9.80BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Cytokinetics Inc is 8.09, ranking 164 out of 389 in the Biotechnology & Medical Research industry. The average price target is 79.00, with a high of 120.00 and a low of 55.00.
Analyst Rating
Based on
22
analysts
Buy
Current Rating
104.474
Target Price
+32.61%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Cytokinetics Inc
CYTK
22
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Cytokinetics Inc's expected revenue for the next quarter?
Cytokinetics Inc's expected revenue is 17.31M.
What is Cytokinetics Inc's price target?
Analysts forecast that Cytokinetics Inc's price target is USD 79.00, with the highest forecast at USD 120.00 and the lowest forecast at USD 55.00.
How have Cytokinetics IncCYTK's recent earnings per share performed?
The market expectation was USD -1.67, while Cytokinetics IncCYTK's earnings per share (EPS) for the previous quarter was USD -1.49. EPS for the next quarter is expected at USD -1.67.
What is the analyst rating for Cytokinetics Inc?
Based on the ratings of Cytokinetics Inc's stock from 22 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
